QuantaMatrix

QuantaMatrix P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of QuantaMatrix (317690.KQ) as of Oct 27, 2026 is -5.19. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -6.07 — a change of -14.51% (higher).

P/FCF

-5.19

YoY

-14.51%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of QuantaMatrix is 2025 -5.19 . P/FCF (Price-to-Free-Cash-Flow Ratio) of QuantaMatrix was 2024 -6.07 . It decreases by -14.51% higher compared to the previous year.

The QuantaMatrix P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
-8.88 KRW
Jan 1, 2019
-5.24 KRW
Jan 1, 2020
-5.70 KRW
Jan 1, 2021
-4.36 KRW
Jan 1, 2022
-4.53 KRW
Jan 1, 2023
-3.63 KRW
Jan 1, 2024
-6.07 KRW
Jan 1, 2025
-5.19 KRW
The QuantaMatrix P/FCF history
YEARP/FCFYoY
-5.19-14.51%
-6.07+67.07%
-3.63-19.89%
-4.53+3.93%
-4.36-23.53%
-5.70+8.86%
-5.24-40.99%
-8.88-24.47%
-11.76—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

QuantaMatrix Stock analysis

What does QuantaMatrix do? QuantaMatrix Inc. generates revenue through the sale of its multi-diagnostic unique test platform, micro disc, antimicrobial susceptibility testing sepsis diagnostic equipment, molecular immunity diagnosis automation platform, rapid antituberculosis susceptibility testing equipment, and rapid antituberculosis susceptibility testing kits. The company also sells covid kits and conducts research and development for microbial diagnostic products. Its primary customers include healthcare facilities and laboratories requiring advanced diagnostic solutions for microbiological and molecular testing. The firm targets segments focused on infectious disease diagnostics, antimicrobial resistance testing, and rapid tuberculosis detection. The company's product portfolio emphasizes innovative diagnostic tools, with a strong focus on sepsis diagnostics and tuberculosis testing. By offering both equipment and kits, QuantaMatrix addresses diverse needs within the healthcare sector. The firm's research and development activities support continuous product enhancement and expansion into new diagnostic areas. QuantaMatrix Inc. serves the global market for diagnostic equipment, with particular emphasis on regions where infectious disease management is critical. Its products are designed to meet the demands of healthcare providers seeking efficient, accurate, and rapid diagnostic solutions. The company's strategy centers on leveraging its technological expertise to capture market share in specialized diagnostic segments. QuantaMatrix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about QuantaMatrix stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of QuantaMatrix is -5.19 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of QuantaMatrix changed from -6.07 to -5.19, representing a -14.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) QuantaMatrix since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s QuantaMatrix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — QuantaMatrix

All Key Metrics — QuantaMatrix